Unknown

Dataset Information

0

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.


ABSTRACT: CCR5 is the major HIV-1 co-receptor, and individuals homozygous for a 32-bp deletion in CCR5 are resistant to infection by CCR5-tropic HIV-1. Using engineered zinc-finger nucleases (ZFNs), we disrupted CCR5 in human CD34(+) hematopoietic stem/progenitor cells (HSPCs) at a mean frequency of 17% of the total alleles in a population. This procedure produces both mono- and bi-allelically disrupted cells. ZFN-treated HSPCs retained the ability to engraft NOD/SCID/IL2rgamma(null) mice and gave rise to polyclonal multi-lineage progeny in which CCR5 was permanently disrupted. Control mice receiving untreated HSPCs and challenged with CCR5-tropic HIV-1 showed profound CD4(+) T-cell loss. In contrast, mice transplanted with ZFN-modified HSPCs underwent rapid selection for CCR5(-/-) cells, had significantly lower HIV-1 levels and preserved human cells throughout their tissues. The demonstration that a minority of CCR5(-/-) HSPCs can populate an infected animal with HIV-1-resistant, CCR5(-/-) progeny supports the use of ZFN-modified autologous hematopoietic stem cells as a clinical approach to treating HIV-1.

SUBMITTER: Holt N 

PROVIDER: S-EPMC3080757 | biostudies-other | 2010 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Holt Nathalia N   Wang Jianbin J   Kim Kenneth K   Friedman Geoffrey G   Wang Xingchao X   Taupin Vanessa V   Crooks Gay M GM   Kohn Donald B DB   Gregory Philip D PD   Holmes Michael C MC   Cannon Paula M PM  

Nature biotechnology 20100702 8


CCR5 is the major HIV-1 co-receptor, and individuals homozygous for a 32-bp deletion in CCR5 are resistant to infection by CCR5-tropic HIV-1. Using engineered zinc-finger nucleases (ZFNs), we disrupted CCR5 in human CD34(+) hematopoietic stem/progenitor cells (HSPCs) at a mean frequency of 17% of the total alleles in a population. This procedure produces both mono- and bi-allelically disrupted cells. ZFN-treated HSPCs retained the ability to engraft NOD/SCID/IL2rgamma(null) mice and gave rise to  ...[more]

Similar Datasets

| S-EPMC3152896 | biostudies-literature
| S-EPMC2502069 | biostudies-literature
| S-EPMC2744961 | biostudies-literature
| S-EPMC2674762 | biostudies-literature
| S-EPMC2900673 | biostudies-literature
| S-EPMC2299223 | biostudies-literature
| S-EPMC3176093 | biostudies-literature